Diffuse Large B Cell Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
  • Leukemia
  • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2022-04-07
    Apr 7, 2022
    W
    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • ONCOLAXY Follow-up
    • Bordeaux, France
    • +4 more
    2022-03-25
    Mar 25, 2022
    A
    Not yet recruiting
    • Follicular Lymphoma
    • +2 more
    • ClonoSEQ
    • Palo Alto, California
      Stanford Cancer Center
    2022-04-04
    Apr 4, 2022
    K
    Completed
    • Diffuse Large B Cell Lymphoma
    • PrednisoLONE 50 MG
    • Busan, Sue-gu, Korea, Republic of
      Kosin University Gospel Hospital
    2022-03-31
    Mar 31, 2022
    J
    Recruiting
    • Non-Hodgkin Lymphoma
    • +4 more
    • JCAR017 (lisocabtagene maraleucel) single-dose schedule
    • JCAR017 (lisocabtagene maraleucel) 2-dose schedule
    • Birmingham, Alabama
    • +13 more
    2022-03-28
    Mar 28, 2022
    K
    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +2 more
    • Goshen, Indiana
    • +39 more
    2022-03-28
    Mar 28, 2022
    D
    Active, not recruiting
    • Hodgkin Lymphoma
    • +2 more
    • Duarte, California
    • +5 more
    2022-03-28
    Mar 28, 2022
    Z
    Recruiting
    • Relapsed Chronic Lymphocytic Leukemia
    • +4 more
    • Phoenix, Arizona
    • +6 more
    2022-03-21
    Mar 21, 2022
    H
    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Central Nervous System Metastasis
      • Herlev, Capital Region, Denmark
        Herlev Hopital
      2022-03-21
      Mar 21, 2022
      F
      Recruiting
      • Diffuse Large B Cell Lymphoma
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      2022-03-13
      Mar 13, 2022
      Z
      Not yet recruiting
      • Diffuse Large B Cell Lymphoma
      • Rituximab, Lenalidomide, Zanubrutinib and RCHOP
      • Hangzhou, Zhejiang, China
        Zhejiang Cancer Hospital
      2022-03-21
      Mar 21, 2022
      H
      Recruiting
      • Diffuse Large B Cell Lymphoma
      • Patient Reported Outcome
      • No intervention
      • Copenhagen, Denmark
        Therese Lassen
      2022-03-18
      Mar 18, 2022
      S
      Not yet recruiting
      • Peripheral T Cell Lymphoma
      • +3 more
      • STI-3031
      • (no location specified)
      2022-03-14
      Mar 14, 2022
      J
      Not yet recruiting
      • B-Cell Lymphoma
      • +8 more
      • Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
      • Pittsburgh, Pennsylvania
        AHN Cancer Institute - West Penn Hospital
      2022-03-08
      Mar 8, 2022
      P
      Recruiting
      • Diffuse Large B Cell Lymphoma
      • High-grade B-cell Lymphoma
      • Darlinghurst, New South Wales, Australia
      • +10 more
      2022-03-10
      Mar 10, 2022
      A
      Active, not recruiting
      • Lymphoma, B-Cell
      • +8 more
      • Scottsdale, Arizona
      • +9 more
      2022-03-10
      Mar 10, 2022
      T
      Recruiting
      • Non Hodgkin Lymphoma
      • Diffuse Large B Cell Lymphoma
      • Nanjing, Jiangsu, China
      • +1 more
      2022-03-09
      Mar 9, 2022
      P
      Recruiting
      • Diffuse Large B Cell Lymphoma
      • Ibrutinib and Bortezomib + R-CHOP
      • Berlin, Germany
        Charité - Universitätsmedizin Berlin, Hematology, Oncology and T
      2022-02-19
      Feb 19, 2022
      T
      Not yet recruiting
      • Diffuse Large B Cell Lymphoma
      • Autologous anti-CD19 CAR-T cell injection
      • (no location specified)
      2022-03-04
      Mar 4, 2022
      F
      Completed
      • Diffuse Large B Cell Lymphoma
      • Treatment plan
      • Milano, MI, Italy
      • +18 more
      2022-02-15
      Feb 15, 2022
      K
      Recruiting
      • Non Hodgkin Lymphoma
      • +3 more
      • Louisville, Kentucky
        Norton Cancer Institute
      2022-03-01
      Mar 1, 2022
      M
      Recruiting
      • Diffuse Large B Cell Lymphoma
      • +8 more
      • 19(T2)28z1xx CAR T cells
      • New York, New York
        Memorial Sloan Kettering Cancer Center
      2022-02-08
      Feb 8, 2022
      U
      Active, not recruiting
      • Classical Hodgkin Lymphoma
      • +12 more
        • Bedford, Bedfordshire, United Kingdom
        • +8 more
        2022-02-22
        Feb 22, 2022